COMPARE · Data as of August 21, 2026
HRMY vs NBIX
Verdict: Side-by-side breakdown using the Bull Rankings model. HRMY scored 88.7, NBIX scored 88.0 — HRMY leads.
Compare another set
HRMY
Harmony Biosciences Holdings, Inc.
88.7
$38.07 · $2.2B
fundamentals as of
Score gap
0.7
HRMY leads
NBIX
Neurocrine Biosciences, Inc.
88
$152.93 · $15.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestHRMY12.3x
- Fastest growthNBIX+34.4%
- Strongest balance sheetNBIX0.12
- Highest qualityNBIX81 / 100
- Largest discount to fair valueHRMY-75%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
HRMY
stronger →← stronger
NBIX
80
Qualityreturns · margins · balance sheet
81
91
Growthrevenue & earnings expansion
96
95
Valuevaluation vs sector peers
88
NBIX is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
HRMY
NBIX
$355mC
FCF
$870mC+
+24.3%A-
Rev
+34.4%A
0.16B+
D/E
0.12B+
12.3xA
P/E
22.4xB+
0.44A
PEG
0.46A
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
HRMY
NBIX
75% below
Price vs fair valuelower is cheaper
11% below
~-18%/yr
Growth the price implies10-yr FCF · lower = less priced in
~8%/yr
+207%
1-yr DCF upside
-6%
+304%
5-yr DCF upside
+12%
+507%
10-yr DCF upside
+46%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
HRMY
Why this score
- Durable high returns
NBIX
Why this score
- Durable high returns
- Diluting shareholders
The companies
HRMYHarmony Biosciences Holdings, Inc.
Why now
Biotechnology · market cap $2.2b. 7% off the 52-week high of $40.87. Revenue growing +24%, comfortably above the S&P median. PEG 0.44 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $46.10 (implying +21% upside).
Moat
Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 196% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
NBIXNeurocrine Biosciences, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $15.5b. 18% off the 52-week high of $186.12. Revenue growing +34% — in hypergrowth territory. PEG 0.46 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $211.57 (implying +38% upside).
Moat
Net margin 21% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 123% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
The model favors HRMY with a 90.7 score over NBIX (87.4), primarily due to HRMY's superior Value pillar score of 93, reflected in its A-grade P/E of 12.4x. A contrarian might prefer NBIX for its higher revenue growth of +34.4% and A-grade PEG of 0.49, though NBIX carries a "Diluting shareholders" signal.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where HRMY and NBIX diverge
On the headline score the gap is 0.7 points in favor of HRMY. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueHRMY 95.4 · NBIX 87.7HRMY +7.7
- GrowthHRMY 91.5 · NBIX 95.9NBIX +4.4
- QualityHRMY 79.9 · NBIX 81.1level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.